Skip to main content
. Author manuscript; available in PMC: 2015 Sep 25.
Published in final edited form as: Cell. 2014 Sep 4;159(1):176–187. doi: 10.1016/j.cell.2014.08.016

Figure 6. Sensitivity to AR and PI3K inhibitor in organoid lines in vitro and in vivo.

Figure 6

A-C. Dose-response curves of organoid lines to enzalutamide, everolimus, and BKM120. Growth was measured in quadruplet and viability was assayed 4 days after treatment at the indicated drug concentrations (Mean +/- SD). D-E. Growth of MSK-PCA1 and MSK-PCA2 xenografts. Treatment was started with tumors reach an average size of 400 mm3. Each tumor was normalized to the pre-treatment size. (N=10, Mean +/-SEM). P value derived from unpaired two-tailed T-test of normalized tumor size at the end of treatment. Ev: everolimus, Enz: enzalutamide, Cast: castration.